ibrexafungerp: Clinical Trials

4 trials of ibrexafungerp, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1

Follow ibrexafungerp: new trials by email Literature Review of ibrexafungerp trials Research Report on ibrexafungerp

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
SCY-078, Voriconazole, Oral Placebo Tablets - Invasive Pulmonary Aspergillosis
Phase 2TerminatedScynexis, Inc.222019-01-222024-08-09
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Fluconazole, SCY-078 - Candida Vulvovaginitis
Phase 2CompletedScynexis, Inc.1862017-08-012021-08-12
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
SCY-078, Fluconazole - Vulvovaginal Candidiasis
Phase 2CompletedScynexis, Inc.962015-11-012019-07-12
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive
Phase 2CompletedScynexis, Inc.272014-09-012024-06-25

Conditions studied

Candidiasis, Vulvovaginal (2)  ·  Aspergillosis (1)  ·  Candidemia (1)  ·  Candidiasis, Invasive (1)  ·  Invasive Pulmonary Aspergillosis (1)  ·  Mycoses (1)

Sponsors

Scynexis, Inc. (4)

Countries

United States (3)  ·  Germany (2)  ·  Belgium (1)  ·  Canada (1)  ·  Dominican Republic (1)  ·  El Salvador (1)  ·  Guatemala (1)  ·  Honduras (1)  ·  South Africa (1)

Top investigators

David Angulo, MD (4)

Results publications

PMID 34555149, PMID 40970688

NIH funding

2018 (1)